BLUE News and Press, bluebird bio Inc. From 12/13/21

bluebird bio (NASDAQ:BLUE) announces updated results from its Phase 1/2 HGB-206 study of lovotibeglogene autotemcel (lovo-cel) gene therapy for sickle cell disease (SCD). Shares up 9.3% premarket at $9.79. In addition to continued complete resolution of severe vaso-occlusive events ...

Arena Pharmaceuticals (NASDAQ:ARNA) +90% on acquisition by Pfizer. Foghorn Therapeutics (NASDAQ:FHTX) +38% after collaborating with Lilly in oncology medicines. BELLUS Health (NASDAQ:BLU) +36% on positive BLU-5937 data in mid-stage chronic cough study. Petros Pha...

Updated data from the pivotal cohort of HGB-206 reinforce that optimized manufacturing and treatment processes are associated with improved biologic and clinical outcomes, including stable production of gene therapy-derived anti-sickling hemoglobin and continued complete resolution of...

BLUE is left with a troubled portfolio with low chances of commercial success, rendering the ticker a speculative trade. The European Medicine Agency's "EMA" decision to authorize two of BLUE's therapies signals higher chances that its portfolio (3 drugs) will receive FDA authorizatio...

Announcing new data from a long-term follow-up study, Bluebird bio (NASDAQ:BLUE) said that 89% of β-thalassemia patients from a key Phase 3 trial remained transfusion-free after receiving beti-cel, its experimental gene therapy for the disease. “These findings further support be...

Oral presentation featured in the ASH press program includes long-term data through August 2021 in patients who achieved transfusion independence (TI) (n=46) and remain transfusion-free through up to seven years of follow-up beti-cel stabilized iron markers in patients who ach...

Although the Healthcare sector is having a positive year in absolute terms, that isn't the case in relative terms. Biotech stocks are having a difficult year, in spite of many of those trading at dirt-cheap valuations that don't even reflect the cash they have in-hand. It's very l...

Vonage (NASDAQ:VG) took the spotlight at the start of a holiday-shortened weak on Monday, soaring in pre-market trading on news of a takeover deal worth more than $6B. The cloud communication provider agreed to be purchased by Ericsson (NASDAQ:ERIC). Zhihu (NYSE:ZH) climbed before the bell, p...

Astra Space (NASDAQ:ASTR) +35% after successful commercial orbital launch iSpecimen (NASDAQ:ISPC) +26% selected by U.S. Government and private researchers to supply critical human biospecimens for advanced phase of COVID-19 research PainReform (NASDAQ:PRFX) +19%. Vonage Holding...

bluebird bio (NASDAQ:BLUE) gains 12% premarket after the FDA accepted for priority review, the Biologics License Application (BLA) for betibeglogene autotemcel (beti-cel). The agency has set a PDUFA goal date of May 20, 2022. Beti-cel is a potentially transformative gene therapy for...